GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cleveland BioLabs Inc (NAS:CBLI) » Definitions » EPS without NRI

Cleveland BioLabs (Cleveland BioLabs) EPS without NRI : $-0.18 (TTM As of Mar. 2021)


View and export this data going back to 2006. Start your Free Trial

What is Cleveland BioLabs EPS without NRI?

Cleveland BioLabs's earnings per share without non-recurring items for the three months ended in Mar. 2021 was $-0.04. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2021 was $-0.18.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 40.30% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 31.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Cleveland BioLabs's EPS without NRI or its related term are showing as below:

CBLI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -196.5   Med: 22   Max: 65.6
Current: 40.3

During the past 13 years, Cleveland BioLabs's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 65.60% per year. The lowest was -196.50% per year. And the median was 22.00% per year.

CBLI's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 4.7 vs CBLI: 40.30

Cleveland BioLabs's EPS (Diluted) for the three months ended in Mar. 2021 was $-0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 was $-0.18.

Cleveland BioLabs's EPS (Basic) for the three months ended in Mar. 2021 was $-0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2021 was $-0.18.


Cleveland BioLabs EPS without NRI Historical Data

The historical data trend for Cleveland BioLabs's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleveland BioLabs EPS without NRI Chart

Cleveland BioLabs Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.24 -0.87 -0.32 -0.23 -0.19

Cleveland BioLabs Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.03 -0.06 -0.05 -0.04

Competitive Comparison of Cleveland BioLabs's EPS without NRI

For the Biotechnology subindustry, Cleveland BioLabs's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cleveland BioLabs's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cleveland BioLabs's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Cleveland BioLabs's PE Ratio without NRI falls into.



Cleveland BioLabs EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cleveland BioLabs  (NAS:CBLI) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cleveland BioLabs EPS without NRI Related Terms

Thank you for viewing the detailed overview of Cleveland BioLabs's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Cleveland BioLabs (Cleveland BioLabs) Business Description

Traded in Other Exchanges
N/A
Address
73 High Street, Buffalo, NY, USA, 14203
Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in the mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for the prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.
Executives
Christopher Zosh officer: Vice President of Finance C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Ivan Fedyunin director 73 HIGH STREET, BUFFALO NY 14203
John Edward Szydlo officer: Principal Financial Officer 73 HIGH STREET, BUFFALO NY 14203
Randy S. Saluck director C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Alexander Andryushechkin director 73 HIGH STREET, BUFFALO NY 14203
Daniil Talyanskiy director 73 HIGH STREET, BUFFALO NY 14203
Alexey Nechaev director 73 HIGH STREET, BUFFALO NY 14203
Lea Verny director 73 HIGH STREET, BUFFALO NY 14203
Tatiana Levina director 10-12 EMMANOUIL ROIDI STR, LIMASSOL G4 CY3031
Ivan Persiyanov director 4 SADOVNICHESKAYA ST, MOSCOW 1Z 115035
Anna Evdokimova director 9-96 UNIVERSITETSKIY PROSPEKT, MOSCOW 1Z 119296
Yulia Lebedina director 5 MALYSHEVA STREET, FLAT 7, MOSCOW 1Z 109129
Konstantin Gorshkov director 10-12 EMMANOUIL ROIDI STR, LIMASSOL G4 CY3031
Natalia Saraeva director 10-12 EMMANOUIL ROIDI STR, LIMASSOL G4 CY3031
Natalia Khudyk director 10-12 EMMANOUIL ROIDI STR, LIMASSOL G4 CY3031

Cleveland BioLabs (Cleveland BioLabs) Headlines

From GuruFocus